Clinical Trial Update: A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver [Phase 1]

View source ↗

Summary

Boehringer Ingelheim is conducting a Phase 1 study comparing BI 456906 with semaglutide to assess glucagon receptor activity in the liver in people with obesity…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• BI 456906
• semaglutide (semaglutide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Obesity | Phase 1 | Status: RECRUITING